Eisai Co., Ltd. announced today that it has entered into a comprehensive marketing agreement with Orion Corporation (Espoo, Finland) concerning Orion's breast cancer drug Fareston(R) (toremifene citrate) and its Parkinson's disease treatment Eldepryl(R)(selegiline hydrochloride).
More info..

Eisai Co., Ltd. announced today that it has signed a statement of intent with the World Health Organization (WHO) to supply free of charge of a primary medicine for the treatment of lymphatic filariasis.
More info..

SymBio Pharmaceuticals Limited and Eisai Co., Ltd. announced today that Eisai's Singapore subsidiary Eisai (Singapore) Pte. Ltd. launched bendamustine hydrochloride ("bendamustine") in Singapore under the brand name Symbenda(R) as a treatment for low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia.
More info..

Eisai Co., Ltd. announced today that the Company's Philippine subsidiary, HI-Eisai Pharmaceutical Inc., launched "REVOVIR(R) 30mg Capsules" (generic name: clevudine) in the Philippines for the treatment of chronic hepatitis B.
More info..

Eisai Co., Ltd. announced today the opening of a regional office in Bahrain. The new office has been established as a branch of its Asian headquarters Eisai Asia Regional Services Pte. Ltd., in Singapore.
More info..